MK-1439
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $974,757 | 741 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $952,664 | 696 | 97.7% |
| Consulting Fee | $16,608 | 8 | 1.7% |
| Travel and Lodging | $4,585 | 18 | 0.5% |
| Food and Beverage | $899.94 | 19 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled ClinicalTrial to Evaluate the Safety and Efficacy of Doravirine MK-1439 100 mg Once DailyVersus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each inCombination with TRUVADA or EPZICOM ,KIVEXA , in Treatment-Na ve HIV-1Infected Subjects | Merck Sharp & Dohme Corporation | $912,337 | 0 |
| Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare theSafety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz PlusTRUVADA in Antiretroviral Treatment-Na ve, HIV-1 Infected Patients | Merck Sharp & Dohme Corporation | $34,611 | 0 |
| A Multiple-Dose Clinical Trial to Study the Effect of MK-1439 doravirine on MethadonePharmacokinetics. | Merck Sharp & Dohme Corporation | $5,717 | 0 |
Top Doctors Receiving Payments for MK-1439
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Atlanta, GA | $952,664 | 696 |
| , M.D., M.P.H | Infectious Disease | Santa Fe, NM | $4,465 | 8 |
| , MD | Internal Medicine | Boston, MA | $3,891 | 8 |
| , M.D | Infectious Disease | Torrance, CA | $3,797 | 9 |
| , M.D | Infectious Disease | Denver, CO | $3,311 | 8 |
| , M.D | Internal Medicine | Philadelphia, PA | $2,875 | 5 |
| , MD | Infectious Disease | Philadelphia, PA | $2,615 | 5 |
| , MD | Hematology & Oncology | San Francisco, CA | $812.50 | 1 |
| Ann Collier | Infectious Disease | Seattle, WA | $325.00 | 1 |
Manufacturing Companies
- Merck Sharp & Dohme Corporation $974,757
Product Information
- Type Drug
- Total Payments $974,757
- Total Doctors 8
- Transactions 741
About MK-1439
MK-1439 is a drug associated with $974,757 in payments to 8 healthcare providers, recorded across 741 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2017. In 2017, $974,757 was paid across 741 transactions to 8 doctors.
The most common payment nature for MK-1439 is "Unspecified" ($952,664, 97.7% of total).
MK-1439 is associated with 3 research studies, including "A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled ClinicalTrial to Evaluate the Safety and Efficacy of Doravirine MK-1439 100 mg Once DailyVersus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each inCombination with TRUVADA or EPZICOM ,KIVEXA , in Treatment-Na ve HIV-1Infected Subjects" ($912,337).